Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

U.S. Senate Committee Advances Azar Nomination as Health Secretary

Reuters Staff  |  January 18, 2018

WASHINGTON (Reuters)—A U.S. Senate committee on Wednesday voted to move forward the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar’s nomination, with all but one Democrat opposing….

Changes in Bone Markers Predict Fracture Reduction with Anti-Resorptive Drug

Will Boggs MD  |  January 17, 2018

NEW YORK (Reuters Health)—Treatment-related changes in bone formation markers predict vertebral-fracture reduction with anti-resorptive drug therapy, according to a meta-regression analysis of 14 clinical trials. “These results may be useful for the development of new osteoporosis treatments or when considering new populations or dosing regimens with existing treatments,” Dr. Douglas C. Bauer from the University…

Wal-Mart Launches Program to Safely Dispose of Unused Opioids

Reuters Staff  |  January 17, 2018

NEW YORK (Reuters)—Wal-Mart Stores Inc on Wednesday said it will provide customers filling prescriptions for opioids with a packet of powder that will help them dispose of leftover medication in order to help curb misuse and abuse. The company said patients filling any new class II opioid prescriptions at its pharmacies will receive a free…

Biosimilars: Still Waiting for Promise to Materialize

Larry Beresford  |  January 17, 2018

During the 2017 ACR/ARHP Annual Meeting, advances in biosimilar treatments were abuzz. However, many speakers noted that the presence of biosimilars on the market has not yet resulted in greater access to treatment and lower drug pricing in the U.S…

Hip Fractures Increasing in Older U.S. Women

Cheryl Platzman Weinstock  |  January 16, 2018

(Reuters Health)—The incidence of hip fractures in older women in the U.S. is rising after more than a decade of decline, according to a large new study of Medicare recipients. Hip fracture rates declined each year from 2002–2012, the researchers found. But starting in 2013, hip fracture rates leveled off and were higher than expected….

Skin Exam Advised Before Anti-TNF-Alpha Therapy

Rita Buckley  |  January 16, 2018

NEW YORK (Reuters Health)—Using tumor necrosis factor alpha (TNF-alpha) inhibitors for atypical dermatoses may unmask, or perhaps even worsen, cutaneous lymphoma, according to new research. “Our findings suggest that careful skin examination might be required in all patients prescribed anti-TNF-alpha agents, especially those with atypical presentations of benign skin conditions,” says Dr. Joan Guitart of…

Rheumatoid Arthritis May Confer Higher Cardiac & Infection Risks

Lorraine L. Janeczko  |  January 16, 2018

NEW YORK (Reuters Health)—Patients with rheumatoid arthritis (RA) are at increased risk of serious infections, myocardial infarction (MI) and coronary heart disease (CHD), an analysis of Medicare claims data suggests. “Higher disease activity as measured by a panel of biomarkers was associated with higher rates of hospitalized infections, MI and CHD events. These findings add…

U.S. Uninsured Rate Up by Most in Nearly a Decade

Yasmeen Abutaleb  |  January 16, 2018

WASHINGTON (Reuters)—The number of Americans without health insurance rose by 3.2 million people between 2016 and 2017, or 1.3% points to 12.2%, according to a Gallup poll released on Tuesday, the biggest jump in the uninsured rate in nearly a decade.1 Several factors likely contributed to the jump, Gallup said, including attempts by Republicans, who…

Bimekizumab Improves Joint & Skin Symptoms in PsA Patients

Michele B. Kaufman, PharmD, BCGP  |  January 16, 2018

Preliminary results from an ongoing study show that bimekizumab improves joint and skin symptoms in patients with psoriatic arthritis…

Physical Assessment of Chronic Fatigue Syndrome: It Just May Work

Lara C. Pullen, PhD  |  January 15, 2018

A recent U.K. study assessed the use of the Perrin technique to diagnose chronic fatigue syndrome based on five physical signs of disease. Overall, researchers found the accuracy of diagnosis by allied health professionals was highest when using tests for only two signs: tender coelic plexus and postural/mechanical disturbances of the thoracic spine…

  • « Previous Page
  • 1
  • …
  • 367
  • 368
  • 369
  • 370
  • 371
  • …
  • 814
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences